Topics

A one-time hemophilia A treatment from Pfizer and Sangamo Therapeutics showed promising results in a small, early-stage study, pointing to a possible future in which patients might have a handful of curative options for the rare bleeding disorder. https:/

10:00 EDT 7 Jul 2019 | STAT

A one-time hemophilia A treatment from Pfizer and Sangamo Therapeutics showed promising results in a small, early-stage study, pointing to a possible future in which patients might have a handful of curative options for the rare bleeding disorder. https://buff.ly/2RZBm38 

Original Article: A one-time hemophilia A treatment from Pfizer and Sangamo Therapeutics showed promising results in a small, early-stage study, pointing to a possible future in which patients might have a handful of curative options for the rare bleeding disorder. https:/

NEXT ARTICLE

More From BioPortfolio on "A one-time hemophilia A treatment from Pfizer and Sangamo Therapeutics showed promising results in a small, early-stage study, pointing to a possible future in which patients might have a handful of curative options for the rare bleeding disorder. https:/"

Quick Search

Relevant Topic

Pfizer
Pfizer is a global pharmaceutical company, the largest in world based on annual sales.  In 2009, annual sales were worth $45,448m. Pfizer spend £550m on R&D in the UK alone, and have colleagues in 180 countries. Lipitor, one of its produ...